Loss of heterozygosity at the SS receptor type 5 locus in human GH- and TSH-secreting pituitary adenomas

M. Filopanti, E. Ballarè, A. G. Lania, S. Bondioni, U. Verga, M. Locatelli, L. M. Zavanone, M. Losa, S. Gelmini, A. Peri, C. Orlando, P. Beck-Peccoz, Anna Spada

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

SS receptor types 2 and 5 (sst2 and sst5) are involved in the control of secretion and proliferation of normal and tumoral somatotrophs and thyrotrophs. The mechanisms leading to reduced responsiveness to SS analogues in patients with pituitary tumors are poorly understood. The aim of the study was to verify the possible loss of heterozygosity (LOH) at the sst5 gene locus in somatotroph and thyrotroph adenomas by screening leukocyte and tumor DNA for two single nucleotide polymorphisms, i.e. C1004T leading to P335L change and T-461C in the 5′-upstream region. Among the 13 informative samples, 1 GH- and 1 TSH-secreting adenoma showed LOH at sst5 gene locus with the retention of Leu335 variant. By analyzing other polymorphic markers spanning from telomere to 16p13.3-13.2 boundaries, DNA deletion of at least 1 megabase was found in both tumors. LOH in thyrotroph adenoma was associated with unusual tumor aggressiveness that required a second surgery and resistance to SS analogs, while no obvious phenotype was identified in the case of the somatotroph adenoma. In conclusions, LOH at the sst5 gene locus is a rare phenomenon, occurring in about 10% of pituitary tumors, that seems to be associated with an aggressive phenotype, at least in thyrotroph adenomas. Further studies are required to confirm this association and to identify the genes, in addition to sst5, lost in these tumors.

Original languageEnglish
Pages (from-to)937-942
Number of pages6
JournalJournal of Endocrinological Investigation
Volume27
Issue number10
Publication statusPublished - Nov 2004

Fingerprint

Growth Hormone-Secreting Pituitary Adenoma
Thyrotrophs
Loss of Heterozygosity
Adenoma
Pituitary Neoplasms
Genes
Neoplasms
Somatotrophs
Phenotype
DNA
Telomere
Single Nucleotide Polymorphism
Leukocytes

Keywords

  • Loss of heterozygosity
  • Somatotroph adenomas
  • SS receptor
  • sst5
  • Thyrotroph adenomas

ASJC Scopus subject areas

  • Endocrinology

Cite this

Loss of heterozygosity at the SS receptor type 5 locus in human GH- and TSH-secreting pituitary adenomas. / Filopanti, M.; Ballarè, E.; Lania, A. G.; Bondioni, S.; Verga, U.; Locatelli, M.; Zavanone, L. M.; Losa, M.; Gelmini, S.; Peri, A.; Orlando, C.; Beck-Peccoz, P.; Spada, Anna.

In: Journal of Endocrinological Investigation, Vol. 27, No. 10, 11.2004, p. 937-942.

Research output: Contribution to journalArticle

Filopanti, M, Ballarè, E, Lania, AG, Bondioni, S, Verga, U, Locatelli, M, Zavanone, LM, Losa, M, Gelmini, S, Peri, A, Orlando, C, Beck-Peccoz, P & Spada, A 2004, 'Loss of heterozygosity at the SS receptor type 5 locus in human GH- and TSH-secreting pituitary adenomas', Journal of Endocrinological Investigation, vol. 27, no. 10, pp. 937-942.
Filopanti, M. ; Ballarè, E. ; Lania, A. G. ; Bondioni, S. ; Verga, U. ; Locatelli, M. ; Zavanone, L. M. ; Losa, M. ; Gelmini, S. ; Peri, A. ; Orlando, C. ; Beck-Peccoz, P. ; Spada, Anna. / Loss of heterozygosity at the SS receptor type 5 locus in human GH- and TSH-secreting pituitary adenomas. In: Journal of Endocrinological Investigation. 2004 ; Vol. 27, No. 10. pp. 937-942.
@article{5d3ed137a2134eb9b9a89f8fdc909787,
title = "Loss of heterozygosity at the SS receptor type 5 locus in human GH- and TSH-secreting pituitary adenomas",
abstract = "SS receptor types 2 and 5 (sst2 and sst5) are involved in the control of secretion and proliferation of normal and tumoral somatotrophs and thyrotrophs. The mechanisms leading to reduced responsiveness to SS analogues in patients with pituitary tumors are poorly understood. The aim of the study was to verify the possible loss of heterozygosity (LOH) at the sst5 gene locus in somatotroph and thyrotroph adenomas by screening leukocyte and tumor DNA for two single nucleotide polymorphisms, i.e. C1004T leading to P335L change and T-461C in the 5′-upstream region. Among the 13 informative samples, 1 GH- and 1 TSH-secreting adenoma showed LOH at sst5 gene locus with the retention of Leu335 variant. By analyzing other polymorphic markers spanning from telomere to 16p13.3-13.2 boundaries, DNA deletion of at least 1 megabase was found in both tumors. LOH in thyrotroph adenoma was associated with unusual tumor aggressiveness that required a second surgery and resistance to SS analogs, while no obvious phenotype was identified in the case of the somatotroph adenoma. In conclusions, LOH at the sst5 gene locus is a rare phenomenon, occurring in about 10{\%} of pituitary tumors, that seems to be associated with an aggressive phenotype, at least in thyrotroph adenomas. Further studies are required to confirm this association and to identify the genes, in addition to sst5, lost in these tumors.",
keywords = "Loss of heterozygosity, Somatotroph adenomas, SS receptor, sst5, Thyrotroph adenomas",
author = "M. Filopanti and E. Ballar{\`e} and Lania, {A. G.} and S. Bondioni and U. Verga and M. Locatelli and Zavanone, {L. M.} and M. Losa and S. Gelmini and A. Peri and C. Orlando and P. Beck-Peccoz and Anna Spada",
year = "2004",
month = "11",
language = "English",
volume = "27",
pages = "937--942",
journal = "Journal of Endocrinological Investigation",
issn = "0391-4097",
publisher = "Springer International Publishing",
number = "10",

}

TY - JOUR

T1 - Loss of heterozygosity at the SS receptor type 5 locus in human GH- and TSH-secreting pituitary adenomas

AU - Filopanti, M.

AU - Ballarè, E.

AU - Lania, A. G.

AU - Bondioni, S.

AU - Verga, U.

AU - Locatelli, M.

AU - Zavanone, L. M.

AU - Losa, M.

AU - Gelmini, S.

AU - Peri, A.

AU - Orlando, C.

AU - Beck-Peccoz, P.

AU - Spada, Anna

PY - 2004/11

Y1 - 2004/11

N2 - SS receptor types 2 and 5 (sst2 and sst5) are involved in the control of secretion and proliferation of normal and tumoral somatotrophs and thyrotrophs. The mechanisms leading to reduced responsiveness to SS analogues in patients with pituitary tumors are poorly understood. The aim of the study was to verify the possible loss of heterozygosity (LOH) at the sst5 gene locus in somatotroph and thyrotroph adenomas by screening leukocyte and tumor DNA for two single nucleotide polymorphisms, i.e. C1004T leading to P335L change and T-461C in the 5′-upstream region. Among the 13 informative samples, 1 GH- and 1 TSH-secreting adenoma showed LOH at sst5 gene locus with the retention of Leu335 variant. By analyzing other polymorphic markers spanning from telomere to 16p13.3-13.2 boundaries, DNA deletion of at least 1 megabase was found in both tumors. LOH in thyrotroph adenoma was associated with unusual tumor aggressiveness that required a second surgery and resistance to SS analogs, while no obvious phenotype was identified in the case of the somatotroph adenoma. In conclusions, LOH at the sst5 gene locus is a rare phenomenon, occurring in about 10% of pituitary tumors, that seems to be associated with an aggressive phenotype, at least in thyrotroph adenomas. Further studies are required to confirm this association and to identify the genes, in addition to sst5, lost in these tumors.

AB - SS receptor types 2 and 5 (sst2 and sst5) are involved in the control of secretion and proliferation of normal and tumoral somatotrophs and thyrotrophs. The mechanisms leading to reduced responsiveness to SS analogues in patients with pituitary tumors are poorly understood. The aim of the study was to verify the possible loss of heterozygosity (LOH) at the sst5 gene locus in somatotroph and thyrotroph adenomas by screening leukocyte and tumor DNA for two single nucleotide polymorphisms, i.e. C1004T leading to P335L change and T-461C in the 5′-upstream region. Among the 13 informative samples, 1 GH- and 1 TSH-secreting adenoma showed LOH at sst5 gene locus with the retention of Leu335 variant. By analyzing other polymorphic markers spanning from telomere to 16p13.3-13.2 boundaries, DNA deletion of at least 1 megabase was found in both tumors. LOH in thyrotroph adenoma was associated with unusual tumor aggressiveness that required a second surgery and resistance to SS analogs, while no obvious phenotype was identified in the case of the somatotroph adenoma. In conclusions, LOH at the sst5 gene locus is a rare phenomenon, occurring in about 10% of pituitary tumors, that seems to be associated with an aggressive phenotype, at least in thyrotroph adenomas. Further studies are required to confirm this association and to identify the genes, in addition to sst5, lost in these tumors.

KW - Loss of heterozygosity

KW - Somatotroph adenomas

KW - SS receptor

KW - sst5

KW - Thyrotroph adenomas

UR - http://www.scopus.com/inward/record.url?scp=19944429893&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=19944429893&partnerID=8YFLogxK

M3 - Article

C2 - 15762041

AN - SCOPUS:19944429893

VL - 27

SP - 937

EP - 942

JO - Journal of Endocrinological Investigation

JF - Journal of Endocrinological Investigation

SN - 0391-4097

IS - 10

ER -